Data suggests combining encorafenib and cetuximab with a FOLFIRI chemotherapy backbone, rather than FOLFOLX, yields superior outcomes in BRAF V600E-mutated metastatic colorectal cancer. This preference is based on both clinical data and a biological rationale that irinotecan synergizes better with MAPK pathway inhibitors.
A Dutch study revealed that hepatic arterial infusion (HAI) pumps did not improve outcomes for high-risk colorectal cancer patients with liver-only metastases post-resection. This disappointing result prompts a strong recommendation to pause the widespread use of HAI pumps outside of clinical trials until more definitive data is available.
The CRYSTAL10 trial, testing adagracib and cetuximab, failed its primary endpoint despite a strong response rate. This suggests targeted RAS inhibitor doublets alone may be insufficient. The likely path forward involves combining them with a chemotherapy backbone, at least for the initial months of treatment, to achieve durable responses.
Minimal Residual Disease (MRD) testing is transitioning from a purely prognostic tool to one with predictive value. Clinicians are beginning to judiciously use MRD results not just to assess risk, but to actively guide personalized management decisions in metastatic colorectal cancer, including assessing immune response in later stages of disease.